Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 17, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - September 17, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/17/14 - "Chitosan Nanofiber for Anionic Protein Drug Delivery, Method of Preparing the Same, and Pharmaceutical Preparation for Transmucosal Administration...
"Chitosan Nanofiber for Anionic Protein Drug Delivery, Method of Preparing the Same, and Pharmaceutical Preparation for Transmucosal Administration Comprising the Chitosan Nanofiber" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors YOO, Hyuk Sang; CHOI, Ji Suk; KIM,
9/17/14 - "Rasagiline for Parkinson'S Disease Modification" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors Levy, Ruth; Eyal, Eli; Goren, Tamar; Oren, Sheila; Sayag, Naim; Weiss, Yonatan; Ben-Ami, Miri, filed on November 27, 2013, was made available online on September 4, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondent
9/17/14 - "Tapentadol Compositions" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventor SESHA, RAMESH, filed on May 13, 2014, was made available online on September 4, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Gruenenthal Gmbh. EP 693,475 and is currentl
9/17/14 - 3SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China
SHENYANG, China, Sept. 1 6, 2014/ PRNewswire/ 3 SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and market
9/17/14 - ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID? Pimavanserin for Parkinson's Disease Psychosis
By a News Reporter-Staff News Editor at Biotech Week ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, announced that the U.S. Food and Drug Administration has granted...
9/17/14 - Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline
By a News Reporter-Staff News Editor at Biotech Week Actavis plc announced that the U.S. Food and Drug Administration has accepted for filing Actavis' New Drug Application for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome. Actavis' NDA for.
9/17/14 - Advancement of Ascendia Pharmaceutical's Nano-Emulsion Technology Platform with Its Lead Development Program ASD-002
By a News Reporter-Staff News Editor at Biotech Week Ascendia Pharmaceuticals, a start-up specialty pharmaceutical company in the business of providing formulation technologies and product development services for poorly soluble molecules, announced that the company has successfully applied its nano-emulsion technology platform to a novel...
9/17/14 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Threshold of Regulation for Substances Used in...
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Threshold of Regulation for Substances Used in Food-Contact Articles. SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled, "Threshold of Regulation for Substances Used in Food-Contact Articles" has been..
9/17/14 - Alios BioPharma to Participate at Upcoming RSV & HCV Scientific Presentations [Manufacturing Close - Up]
Alios BioPharma will be presenting data at several scientific meetings. Meeting: IDWeek 2014 to be held in Philadelphia, PA from October 8- 12. Meeting: AASLD The Liver Meeting to be held in Boston, MA from November 7- 11.
9/17/14 - Alnylam Bolsters Pipeline with ALN-AGT for the Treatment of Hypertensive Disorders of Pregnancy [Manufacturing Close - Up]
Alnylam Pharmaceuticals, Inc. reported that it is broadening its pipeline with ALN-AGT, a subcutaneously administered RNAi therapeutic targeting angiotensinogen for the treatment of hypertensive disorders of pregnancy, including preeclampsia, one of the most common complications of pregnancy. According to a company release, in a poster presented at
9/17/14 - Alnylam to Webcast Presentation at Morgan Stanley Global Healthcare Conference
By a News Reporter-Staff News Editor at Biotech Week Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2014 at 10:20 a.m. ET at the Grand Hyatt in New York City. The company's demonstrated comm
9/17/14 - Amarin Posts Update on ANCHOR Trial SPA Agreement Rescission Appeal [Professional Services Close - Up]
Amarin reported that the Office of New Drugs within the U.S. Food and Drug Administration has denied Amarin's appeal of FDA's rescission of the ANCHOR clinical trial Special Protocol Assessment agreement. Amarin continues to believe that reinstatement of this SPA agreement and approval of an indication based on the ANCHOR clinical trial results is
9/17/14 - Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry - 2014
Dublin- Research and Markets has announced the addition of the "Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry- 2014" report to their offering. This research presents Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry- a comprehensive coverage of the generic drugs market in the United States. Strategies for s
9/17/14 - Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Release date- 16092014- Berlin,- Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational novel oral androgen receptor inhibitor in clinical development for the treatment of patients with prostate cancer. The study, called ARAMIS, ev
9/17/14 - Biogen Idec and AbbVie Issues Phase 3 Decide Study Results [Manufacturing Close - Up]
Biogen Idec and AbbVie released the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. According to a media release, these results are b
9/17/14 - Clearside Biomedical, Inc. Completes $16 Million Series B Financing
By a News Reporter-Staff News Editor at Biotech Week Clearside Biomedical, Inc., announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.
9/17/14 - Clinical trial to test safety of drug targeting leukemia cells
By a News Reporter-Staff News Editor at Biotech Week Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine and Celgene Corporation, a New Jersey- based biopharmaceutical company, have launched a phase 1 human clinical trial to assess the safety and efficac
9/17/14 - Copy our I-phones not our diets [Prevention (India)]
The American cardiologist Dr Dean Ornish believes that copying the takeaway-culture and push-button lifestyles of the West has resulted in the sharp rise in lifestyle diseases in India. Here's a prescription for finding the right way.Dr Dean Ornish, 61, the founder and president of the non-profit Preventive Medicine Research Institute and Clinical.
9/17/14 - Dr. Jeanne M. Novak, President & CEO Of CBR International Corp., To Attend World Health Organization WHO Meeting To Address Leading Experimental...
Jeanne M. Novak, President and CEO of Boulder, Colorado- based CBR International Corp., a full-service biopharmaceutical product, clinical, medical device and regulatory development and compliance group, has been invited by Dr. Working side-by-side with Mapp Biopharmaceutical, Inc., Kentucky Bioprocessing, Emory University Hospital, ELWA Hospital,
9/17/14 - Draft Guidance for Industry on Abbreviated New Drug Application SubmissionsRefuse To Receive for Lack of Proper Justification of Impurity Limits;...
This draft guidance is intended to assist applicants preparing to submit to FDA abbreviated new drug applications and related submissions for which the applicant is seeking approval of a new strength of the drug product. The draft guidance highlights deficiencies about impurity information that may cause FDA to refuse to receive an ANDA.
9/17/14 - FDA approves MOVANTIK (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain
Release date- 16092014- AstraZeneca today announced that the US Food and Drug Administration approved MOVANTIK tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation, in adult patients with chronic, non-cancer pain. Briggs Morrison, Executive Vice...
9/17/14 - FDA weighs risks of testosterone replacement medicines [The Philadelphia Inquirer]
In January, the U.S. Food and Drug Administration issued a "safety announcement," to say it was "investigating the risk of stroke, heart attack, and death in men taking FDA- approved testosterone products." The agency said patients should not stop taking prescribed products without talking to a health-care professional, but also said, those "profes
9/17/14 - GE Healthcare Announces FDA Approval of SenoClaire, New Breast Imaging with 3D Tomosynthesis Solution
By a News Reporter-Staff News Editor at Biotech Week GE Healthcare announced the FDA approval of SenoClaire*, GE's new breast tomosynthesis solution designed with a three-dimensional imaging technology. Daniel Kopans, Senior Radiologist, Breast Imaging Division Department of Radiology, Massachusetts General Hospital. Murray Rebner MD, FACR, Profe
9/17/14 - Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries
Release date- 16092014- NEW DELHI- Gilead Sciences, Inc. today announced that the company has signed non-exclusive licensing agreements with seven India- based generic pharmaceutical manufacturers to expand access to its chronic hepatitis C medicines in developing countries. The agreements allow the companies- Cadila Healthcare Ltd., Cipla Ltd., He
9/17/14 - Global Gene Therapy Market Outlook 2018
Dublin- Research and Markets has announced the addition of the "Global Gene Therapy Market Outlook 2018" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. Unlike other regions globally, the United St
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415